Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amplify Weight Loss Drug & Treatment ETF (THNR)

Amplify Weight Loss Drug & Treatment ETF (THNR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Amplify ETFs
  • Assets Under Management 3,022,000
  • Shares Outstanding, K 130
  • 60-Month Beta N/A
  • Price/Earnings ttm N/A
  • Annual Dividend & Yield 0.22 (0.95%)
  • Most Recent Dividend 0.220 on 12/30/24
  • Management Fee 0.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.31 +2.96%
on 06/23/25
23.95 -4.09%
on 06/12/25
-0.70 (-2.94%)
since 06/11/25
3-Month
19.68 +16.70%
on 04/16/25
23.95 -4.09%
on 06/12/25
+3.26 (+16.53%)
since 04/11/25
52-Week
18.56 +23.76%
on 04/07/25
28.19 -18.53%
on 08/30/24
-3.76 (-14.07%)
since 07/11/24

Most Recent Stories

More News
Weight Loss Drug ETF (THNR) Hits New 52-Week High

Amplify Weight Loss Drug & Treatment ETF THNR is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 51.9% from its 52-week low price of $18.56/share.Are...

NVO : 68.93 (-2.93%)
LLY : 793.01 (+0.30%)
THNR : 22.97 (-1.34%)
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss medicine...

OZEM : 25.88 (-1.03%)
IHE : 67.18 (-0.75%)
LLY : 793.01 (+0.30%)
MEDX : 27.83 (-0.78%)
PPH : 88.23 (-1.26%)
THNR : 22.97 (-1.34%)
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR

For Immediate ReleaseChicago, IL – October 17, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 68.93 (-2.93%)
LLY : 793.01 (+0.30%)
HRTS : 28.84 (-1.50%)
PPH : 88.23 (-1.26%)
THNR : 22.97 (-1.34%)
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global...

NVO : 68.93 (-2.93%)
LLY : 793.01 (+0.30%)
HRTS : 28.84 (-1.50%)
PPH : 88.23 (-1.26%)
THNR : 22.97 (-1.34%)
Tap the Weight-Loss Drug Market With These ETFs

The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are...

NVO : 68.93 (-2.93%)
OZEM : 25.88 (-1.03%)
LLY : 793.01 (+0.30%)
HRTS : 28.84 (-1.50%)
RHHBY : 40.4900 (-1.77%)
THNR : 22.97 (-1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Fund Summary

The Amplify Weight Loss Drug and Treatment ETF seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug and Treatment Index.

See More

Top 10 Holdings

Name % Holdings
Eli Lilly and Company 12.41%
Novo Nordisk A/S ADR 11.01%
Regeneron Pharmaceuticals 7.21%
Amgen Inc 6.90%
N/A 6.34%
Pfizer Inc 5.27%
Gilead Sciences Inc 5.15%
Merck & Company 5.10%
Abbvie Inc 5.08%
N/A 4.98%

See More

Key Turning Points

3rd Resistance Point 23.10
2nd Resistance Point 23.04
1st Resistance Point 23.00
Last Price 22.97
1st Support Level 22.90
2nd Support Level 22.84
3rd Support Level 22.80

See More

52-Week High 28.19
Fibonacci 61.8% 24.51
Fibonacci 50% 23.38
Last Price 22.97
Fibonacci 38.2% 22.24
52-Week Low 18.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar